Neurocrine Biosciences, Inc. (NBIX)
153.04
+0.47
(+0.31%)
USD |
NASDAQ |
Aug 24, 16:00
153.04
0.00 (0.00%)
After-Hours: 19:57
Neurocrine Biosciences EPS Diluted (Quarterly) : 1.386 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.386 |
| March 31, 2026 | 1.914 |
| December 31, 2025 | 1.482 |
| September 30, 2025 | 2.044 |
| June 30, 2025 | 1.064 |
| March 31, 2025 | 0.0771 |
| December 31, 2024 | 1.002 |
| September 30, 2024 | 1.244 |
| June 30, 2024 | 0.6256 |
| March 31, 2024 | 0.4189 |
| December 31, 2023 | 1.444 |
| September 30, 2023 | 0.822 |
| June 30, 2023 | 0.9531 |
| March 31, 2023 | -0.7889 |
| December 31, 2022 | 0.8829 |
| September 30, 2022 | 0.6919 |
| June 30, 2022 | -0.1768 |
| March 31, 2022 | 0.1424 |
| December 31, 2021 | -0.0769 |
| September 30, 2021 | 0.2303 |
| June 30, 2021 | 0.433 |
| March 31, 2021 | 0.3269 |
| December 31, 2020 | 3.579 |
| September 30, 2020 | -0.6174 |
| June 30, 2020 | 0.8106 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.3856 |
| December 31, 2019 | 0.3498 |
| September 30, 2019 | 0.5599 |
| June 30, 2019 | 0.5417 |
| March 31, 2019 | -1.121 |
| December 31, 2018 | 0.1889 |
| September 30, 2018 | 0.5244 |
| June 30, 2018 | -0.0656 |
| March 31, 2018 | -0.4671 |
| December 31, 2017 | 0.07 |
| September 30, 2017 | -0.126 |
| June 30, 2017 | -0.68 |
| March 31, 2017 | -0.90 |
| December 31, 2016 | -0.51 |
| September 30, 2016 | -0.43 |
| June 30, 2016 | -0.46 |
| March 31, 2016 | -0.22 |
| December 31, 2015 | -0.34 |
| September 30, 2015 | -0.40 |
| June 30, 2015 | -0.28 |
| March 31, 2015 | -0.01 |
| December 31, 2014 | -0.26 |
| September 30, 2014 | -0.21 |
| June 30, 2014 | -0.18 |
| March 31, 2014 | -0.17 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Amarin Corp. Plc | -0.3681 |
| Liquidia Corp. | 0.7369 |
| Incyte Corp. | 2.812 |
| Krystal Biotech, Inc. | 1.786 |
| Halozyme Therapeutics, Inc. | 1.897 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 144.40M |
| Revenue (Quarterly) | 959.00M |
| Total Expenses (Quarterly) | 814.60M |
| Enterprise Value | 15.51B |
| Gross Profit Margin (Quarterly) | 95.87% |
| Profit Margin (Quarterly) | 15.06% |
| Earnings Yield | 4.46% |
| Operating Earnings Yield | 5.09% |
| Normalized Earnings Yield | 4.371 |